Overview

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Status:
Not yet recruiting

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)

Phase:

Phase 2

Details

Lead Sponsor:

Centre Hospitalier Universitaire de Besancon

Collaborator:

GERCOR - Multidisciplinary Oncology Cooperative Group

Treatments:

Atezolizumab
Bevacizumab